Stephen K. Tahir
AbbVie (United States)(US)
Publications by Year
Research Areas
Cell death mechanisms and regulation, Cancer therapeutics and mechanisms, Lung Cancer Research Studies, Synthesis and Characterization of Heterocyclic Compounds, Peptidase Inhibition and Analysis
Most-Cited Works
- → An inhibitor of Bcl-2 family proteins induces regression of solid tumours(2005)3,369 cited
- → ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets(2013)2,976 cited
- → ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor(2008)1,942 cited
- → Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy(2015)535 cited
- → Discovery of a Potent and Selective BCL-X L Inhibitor with in Vivo Activity(2014)328 cited
- → Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737(2007)301 cited
- → Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins(2008)291 cited
- → Down-regulation of Survivin by Antisense Oligonucleotides Increases Apoptosis, Inhibits Cytokinesis and Anchorage-Independent Growth(2000)211 cited
- → Potential mechanisms of resistance to venetoclax and strategies to circumvent it(2017)186 cited
- Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208(2013)